Your browser doesn't support javascript.
loading
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.
Zelenetz, Andrew D; Gordon, Leo I; Chang, Julie E; Christian, Beth; Abramson, Jeremy S; Advani, Ranjana H; Bartlett, Nancy L; Budde, L Elizabeth; Caimi, Paolo F; De Vos, Sven; Dholaria, Bhagirathbhai; Fakhri, Bita; Fayad, Luis E; Glenn, Martha J; Habermann, Thomas M; Hernandez-Ilizaliturri, Francisco; Hsi, Eric; Hu, Boyu; Kaminski, Mark S; Kelsey, Christopher R; Khan, Nadia; Krivacic, Susan; LaCasce, Ann S; Lim, Megan; Narkhede, Mayur; Rabinovitch, Rachel; Ramakrishnan, Praveen; Reid, Erin; Roberts, Kenneth B; Saeed, Hayder; Smith, Stephen D; Svoboda, Jakub; Swinnen, Lode J; Tuscano, Joseph; Vose, Julie M; Dwyer, Mary A; Sundar, Hema.
Affiliation
  • Zelenetz AD; Memorial Sloan Kettering Cancer Center.
  • Gordon LI; Robert H. Lurie Comprehensive Cancer Center of Northwestern University.
  • Chang JE; University of Wisconsin Carbone Cancer Center.
  • Christian B; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.
  • Abramson JS; Massachusetts General Hospital Cancer Center.
  • Advani RH; Stanford Cancer Institute.
  • Bartlett NL; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.
  • Budde LE; City of Hope National Medical Center.
  • Caimi PF; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.
  • De Vos S; UCLA Jonsson Comprehensive Cancer Center.
  • Dholaria B; Vanderbilt-Ingram Cancer Center.
  • Fakhri B; UCSF Helen Diller Family Comprehensive Cancer Center.
  • Fayad LE; The University of Texas MD Anderson Cancer Center.
  • Glenn MJ; Huntsman Cancer Institute at the University of Utah.
  • Habermann TM; Mayo Clinic Cancer Center.
  • Hernandez-Ilizaliturri F; Roswell Park Comprehensive Cancer Center.
  • Hsi E; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute.
  • Hu B; Huntsman Cancer Institute at the University of Utah.
  • Kaminski MS; University of Michigan Rogel Cancer Center.
  • Kelsey CR; Duke Cancer Institute.
  • Khan N; Fox Chase Cancer Center.
  • Krivacic S; Consultant.
  • LaCasce AS; Dana-Farber/Brigham and Women's Cancer Center.
  • Lim M; Abramson Cancer Center at the University of Pennsylvania.
  • Narkhede M; O'Neal Comprehensive Cancer Center at UAB.
  • Rabinovitch R; University of Colorado Cancer Center.
  • Ramakrishnan P; UT Southwestern Simmons Comprehensive Cancer Center.
  • Reid E; UC San Diego Moores Cancer Center.
  • Roberts KB; Yale Cancer Center/Smilow Cancer Hospital.
  • Saeed H; Moffitt Cancer Center.
  • Smith SD; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.
  • Svoboda J; Abramson Cancer Center at the University of Pennsylvania.
  • Swinnen LJ; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
  • Tuscano J; UC Davis Comprehensive Cancer Center.
  • Vose JM; Fred & Pamela Buffett Cancer Center; and.
  • Dwyer MA; National Comprehensive Cancer Network.
  • Sundar H; National Comprehensive Cancer Network.
J Natl Compr Canc Netw ; 19(11): 1218-1230, 2021 11.
Article in En | MEDLINE | ID: mdl-34781267
In the last decade, a better understanding of the molecular pathogenesis of B-cell non-Hodgkin lymphomas has resulted in the development of novel targeted therapies, such as small molecule inhibitors of select kinases in the B-cell receptor pathway, antibody-drug conjugates, and small molecules that target a variety of proteins (eg, CD-19, EZH2, and XPO-1-mediated nuclear export). Anti-CD19 CAR T-cell therapy, first approved for relapsed/refractory (R/R) diffuse large B-cell lymphoma, has also emerged as a novel treatment option for R/R follicular lymphoma and mantle cell lymphoma. These NCCN Guideline Insights highlight the new targeted therapy options included in the NCCN Guidelines for B-Cell Lymphomas for the treatment of R/R disease.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Non-Hodgkin / Lymphoma, Large B-Cell, Diffuse / Immunoconjugates Type of study: Guideline Limits: Adult / Humans Language: En Journal: J Natl Compr Canc Netw Journal subject: NEOPLASIAS Year: 2021 Type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Non-Hodgkin / Lymphoma, Large B-Cell, Diffuse / Immunoconjugates Type of study: Guideline Limits: Adult / Humans Language: En Journal: J Natl Compr Canc Netw Journal subject: NEOPLASIAS Year: 2021 Type: Article